ACLS Bradycardia Management Quiz

The recommended initial pacing rate during transcutaneous pacing in ACLS is 100 beats per minute to address symptomatic bradycardia effectively.

The primary goal of treating bradycardia in ACLS is to increase heart rate and improve cardiac output, enhancing perfusion to vital organs.

The primary mechanism of action of atropine in managing bradycardia is negative chronotropy, inhibiting vagal influences and increasing heart rate.

In bradycardia, the primary effect of atropine on the heart is to increase heart rate by blocking vagal influences and promoting sympathetic activity.

The primary mechanism of action of dopamine in managing bradycardia in ACLS is positive inotropy, enhancing myocardial contractility and increasing heart rate.

Atropine is the first-line drug for treating symptomatic bradycardia in ACLS, acting by blocking vagal effects and increasing heart rate.

Atropine should be administered at a rate of 0.5 mg every 3-5 minutes in ACLS bradycardia management to achieve the desired effect.

Glucagon is indicated for bradycardia caused by beta-blocker or calcium channel blocker toxicity in ACLS, offering an alternative mechanism to increase heart rate.

The recommended dose of dopamine in ACLS bradycardia management is 10-20 mcg/kg/min, providing positive inotropic support to increase heart rate.

For a patient with a heart rate less than 60 beats per minute in ACLS bradycardia management, the recommended dose of atropine is 1 mg to prompt an increase in heart rate.

Various reversible causes such as hypovolemia, hypoxia, and acidosis contribute to bradycardia in ACLS, making 'All of the above' the correct answer.

The recommended dose of epinephrine in symptomatic bradycardia according to ACLS guidelines is 0.5 mg every 3-5 minutes, aiming to increase heart rate.

Transcutaneous pacing is considered the most effective method in ACLS for managing bradycardia with inadequate perfusion despite atropine, directly controlling the heart rate.

The recommended initial energy setting for transcutaneous pacing in ACLS is 100 mA to establish effective pacing and address symptomatic bradycardia.

Conduction system disease is NOT a reversible cause of bradycardia in ACLS, as it pertains to intrinsic abnormalities in the heart's electrical conduction.